ResMed Inc.’s Stock Price Soars to $236.10, Marking a Stellar 10.10% Uptick

ResMed Inc. (RMD)

236.10 USD +21.66 (+10.10%) Volume: 2.26M

ResMed Inc.’s stock price soared to 236.10 USD, marking an impressive trading session increase of +10.10%, driven by a robust trading volume of 2.26M. With a year-to-date percentage change of +3.24%, RMD’s stock performance continues to show promising growth potential.

Latest developments on ResMed Inc.

ResMed Inc. stock rose on Thursday, outperforming the market, following the release of their strong Q3 2025 earnings report. The company reported strong revenue growth, beating earnings and revenue estimates, leading to a surge in stock price. ResMed’s strategic market positioning in sleep solutions and recent tariff exemptions have also boosted investor confidence, with analysts raising price forecasts. The company’s focus on US manufacturing strategy and consistent quarterly dividend announcements have further contributed to the positive stock movements. Overall, ResMed’s double-digit EPS growth and strong financial results have positioned the company as a key player in the market, with a target price raised to $255 by RBC Capital.

ResMed Inc. on Smartkarma

Analysts from Baptista Research on Smartkarma have published insightful research reports on ResMed Inc. The first report, titled “ResMed: How Sleep Apnea Awareness is Expanding Global Market Potential! – Major Drivers,” highlights the company’s second quarter fiscal year 2025 earnings presentation. ResMed Inc. showed notable financial and operational results, with a 10% global revenue increase to $1.28 billion. Device sales and masks/accessories sales both rose by 11%, indicating strong performance across key business sectors.

In another report by Baptista Research, titled “ResMed Inc.: Expanding Patient Access and Engagement with Technology To Catalyze Growth! – Major Drivers,” the focus is on the company’s Q1 Fiscal Year 2025 earnings report. The report showcases a strong start to the year, with an 11% revenue increase driven by robust demand for sleep health products and software offerings. Baptista Research evaluates various factors that could impact ResMed Inc.’s stock price in the near future, conducting an independent valuation using a Discounted Cash Flow methodology.

A look at ResMed Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma’s Smart Scores, Resmed Inc has a promising long-term outlook. With strong scores in Growth, Resilience, and Momentum, the company is positioned well for future success. Its focus on developing, manufacturing, and marketing medical equipment for sleep disordered breathing treatment shows potential for continued growth and market expansion.

While Resmed Inc may not score as high in Value and Dividend factors, its overall outlook remains positive. The company’s emphasis on innovation and market presence bodes well for its future performance. With a solid foundation in the healthcare industry, Resmed Inc is likely to continue making strides in providing solutions for sleep disorders globally.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma